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Abstract
Diabetes is a debilitating disease process caused by the body’s inability to control blood glucose
levels. With over 30 million diabetics in the United States, and another 85 million prediabetics,
the effects of this disease are wide-spread and far-reaching. Native American/Alaska Native
populations have a nearly two-fold increase in incidence of diabetes when compared to nonnative populations. Risk factors for diabetes in all populations include modifiable risks such as
obesity, diet, physical inactivity as well as non-modifiable factors such as age, family history,
and ethnicity. Studies have shown that early identification of symptoms, coupled with proper and
intentional treatment can delay the onset of diabetes. The purpose of this project is to determine
the efficacy of currently recognized best-practice therapies in Native American patients and to
identify barriers to successful implementation of such practices in the Native American
population. A thorough review of the available literature shows that research of this topic
specific to the Native American population is lacking. However, evidence suggests that the
broad, general population recommendations made by the American Diabetes Association in their
Standards of Medical Care in Diabetes (2018) will be equally effective in the Native American
population when applied objectively. It is also recognized that Native Americans face additional
barriers in the effort to identify and treat diabetes. These include geographic, economic, and
social factors that inhibit treatment efficacy and ultimately lead to increased morbidity in this
population.
Keywords: diabetes, prediabetes, American Indian, Native American, diabetes treatment,
obesity, glucose, genetic predisposition, pharmacotherapy, ethnicity, insulin, and lifestyle
modifications
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Introduction
Diabetes is a major factor in the overall health of the U.S. population. It is broadly
defined as a fasting plasma glucose of >126mg/dl, a hemoglobin A1c > 6.5%, or a glucose
tolerance test of >200mg/dl. According to the Centers for Disease Control (CDC), more than 30
million Americans are diabetic and another 85 million are considered prediabetic, with an A1c of
5.7% - 6.4% or a fasting plasma glucose of 100-125 mg/dl. Over the past 20 years, the number of
Americans with diabetes has tripled. This is an alarming rate that carries significant health and
financial burdens for those affected, their families, and for the entire nation. Additionally, with
nearly one-third of the U.S. population experiencing prediabetic conditions (CDC, 2018), the
importance of identification, diagnosis and early treatment is increasingly important.
With an estimated total population of 6.795 million, Native Americans, which include
American Indians and Alaska Natives, make up approximately 2% of the total United States
population as of 2017 (U.S. Census Bureau, 2018). According to the CDC, the prevalence of
diabetes in this population is 16%, which equates to nearly 1.1 million Native American
diabetics. When compared to the Caucasian population, a two-fold increase in diabetes
prevalence is observed. In fact, when compared to all races, Native Americans exhibit a greater
chance of having diabetes than any other racial group.
Diabetes is encountered daily by nearly all clinicians in the rural primary care setting.
Because many diabetic patients also present with co-morbid conditions including hypertension
and obesity, among other chronic diseases, their treatment plans are often more complex and
difficult to manage. In addition to these medical complexities, other issues including financial,
geographical, and motivational barriers have been identified as contributory to the current
diabetes epidemic within the Native American population.
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Social effects are evident as diabetes management requires strict adherence to diet,
exercise, and medication regimens, which are time-consuming and tedious. Often, these
constraints are not conducive to the lifestyles of their non-diabetic friends and family members,
leading to a social isolation for diabetic patients when efforts are made to control their blood
sugars through lifestyle modifications. The mental effects of diabetes can also play a devastating
role in the overall health of an individual. According to a study by Holt, de Groot and Golden
(2014), given the detrimental effects of the disease, diabetic patients are 2 to 3 times more likely
to develop depression than those without the disease.
Diabetes continues to be a major health problem in the Native American population.
Because of the devastating effects of diabetes on the kidneys, eyes, heart, and other systems, it
remains vitally important to identify patients at risk and treat symptoms that are evident prior to
its onset. Within the last two decades, major improvements have been made in the management
of diabetes, specifically within the Native American community through the Diabetes Prevention
Program and the efforts of local tribal entities. However, the disease remains a major cause of
morbidity and mortality amongst this population.
Current treatment recommendations from the American Diabetes Association (ADA)
include diabetes self-management, education, and support in addition to nutrition therapy, weight
management, and physical activity. Although the ADA applies these recommendations to
patients of all ethnicities, it also acknowledges social contexts that may require treatment
strategies tailored to population-specific needs. Barriers to ideal treatment remain paramount
when considering the discordance of diabetes in Native Americans and social contexts must be
favorably considered as the healthcare community seeks to reduce the incidence and prevalence
of diabetes in this population.
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The goal of this study is to determine the benefits of lifestyle and pharmacologic
interventions in pre-diabetic and diabetic Native American patients and to identify barriers that
may lead to ineffectiveness of such interventions.

Statement of the Problem
According to McLaughlin (2010), diabetes and other chronic illnesses were virtually nonexistent in the Native American population at the turn of the 20th century. Until the early 1970s,
diabetes was not in the top 10 causes of death for this population. By 2009, however, diabetes
had climbed to number four on this list, and today, more than one in six Native Americans is
diagnosed with diabetes.
The benefits of blood glucose management through lifestyle modification therapies are
well known and clinically proven (Powers, et al. 2015). According to the ADA’s Standards of
Medical Care in Diabetes (2018) lifestyle management is a fundamental aspect of diabetes care
and includes self-management education and support (DSMES), medical nutrition therapy
(MNT), physical activity, smoking cessation counseling, and psychosocial care. These
recommendations are strongly supported by evidence from well-conducted, generalizable studies
and meta-analyses, earning “A” and “B” ratings from the ADA. Despite the widely known
benefits of these interventions, many do not begin until the patient is diagnosed with diabetes,
and often not until advanced disease is present. While this is also true in the general population,
it appears to be more prevalent in the Native American population. According to Lillie-Blanton
and Roubideaux (2005), there is significant evidence to conclude that Native Americans are
disadvantaged in the healthcare system due to disparities in healthcare financing, access to care,
and quality of care. Because many factors can influence this delayed intervention, the
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ramifications for patients are certainly deleterious as damage to delicate tissues such as eyes,
kidneys, and other microvasculature may have already progressed. Given the prevalence of
diabetes in the Native American population, special attention must be paid to better understand
the barriers that exist and ultimately deter patients from receiving optimal care and to determine
the most appropriate and clinically sound treatment plans for these patients. Research must be
focused on finding opportunities to identify and treat patients before the onset of diabetes.

Research Questions
In Native American patients, can lifestyle and pharmacologic interventions, prior to the onset of
diabetes, improve glucose tolerance?

Are there additional benefits of combined therapy with metformin and lifestyle modifications
that could improve the quality of life for these patients?

Are there identifiable barriers to successful treatment of prediabetes and diabetes in the Native
American population?

Research Methods
For this literature review, CINAHL, Clinical Key, Cochrane, PubMed and ScienceDirect
databases, as well as selected articles were searched to provide an overview of current evidence
related to the topic of diabetes treatment, both in general as well as within the Native American
population. The search included the following key words and MeSH terms: diabetes, prediabetes,
American Indian, Native American, diabetes treatment, obesity, glucose, genetic predisposition,
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pharmacotherapy, and lifestyle modifications. The initial search included eight years (2010present) and was expanded to 15 years (2003-present) as a landmark study—the Strong Heart
study (and subsequent sub-studies)—was considered critical enough to warrant inclusion. While
studies related to prediabetes, diabetes and treatment options were plentiful, those specific to the
Native American population were not readily available. Therefore, articles were included if they
contained applicable information or data related to the research questions, regardless of ethnic
focus. This was not a systematic review of all published articles regarding prediabetes, diabetes
and treatment options. The research for this article primarily reviewed current prediabetes and
diabetes treatment recommendations, their effects on the health of the participants and
translational abilities of such studies to the Native American population.

Literature Review
Review of the literature on lifestyle and pharmacological interventions to reduce the
incidence and effects of type II diabetes mellitus (DMII) has shown marked benefits with several
specific therapies. These include limited diabetic education, intensive and non-intensive lifestyle
modification programs (Powers, et al. 2015), metformin therapy (Ramachandran, et al. 2006),
and more recently, newer antidiabetic medications such as DPP-4 inhibitors (Dicker, 2011).
While all such interventions have proven beneficial in patients with impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT), some are more efficacious than others. Although
much of the available literature is not specific to the Native American population, evidence is
suggestive of similar benefits in all patients with impaired glucose tolerance. Additionally,
genetic, behavioral and socio-economic factors have been implicated in the development of
diabetes, despite availability of effective therapies. Given the high prevalence of diabetes in the
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Native American population, the results of further study may pay dividends as populationspecific approaches to diabetes care are identified and successfully demonstrated.

Pathophysiology of Type 2 Diabetes
Although there are several recognized disorders under the diabetes umbrella, type 2
diabetes—a complex disease related to the body’s ability to produce and utilize insulin—is by far
the most commonly diagnosed throughout the world. In type 2 diabetes, patients exhibit an array
of dysfunction including resistance to insulin activity, inadequate insulin secretion, and
inappropriate glucagon secretion. In healthy individuals, the pancreas produces insulin which is
used by the body to allow cells to take up glucose from the blood stream to be used in
metabolism and energy production. When adequate energy stores are present, excess glucose
from the blood is stored in the liver in the form of glycogen. If energy needs increase or levels
fall, and sufficient glucose levels in the blood are not available, the pancreas produces glucagon.
This acts to release stored energy, in the form of glycogen, from the liver and into circulation
where it can be utilized by peripheral tissues for energy production. When insulin fails to
function appropriately—termed insulin resistance—patients can be diagnosed with prediabetes.
In this setting, patients can present with increased blood glucose levels at either fasting or
post-tolerance test points. When the body senses increased blood glucose levels, the natural
response is to increase the production of insulin from the pancreatic beta cells. Insulin levels will
rise in an effort to assist glucose into the cells where it can be utilized for energy production.
However, due to insulin resistance, these cells no longer respond to insulin efficiently. Blood
glucose levels remain high, which fails to initiate the negative feedback loop on insulin
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production. With the increased demand on the pancreatic beta cells, they naturally begin to fail
over time, leading to insulin-dependent status for these patients.
Although diabetes is a complex disease process, screening tests for diabetes are simple
and primarily focused on glycemia—how much glucose is in the blood. That focus, however,
may be too narrow to identify patient-specific disease stages and ultimately limit our ability to
treat patients effectively. According to Rosenstock (2007), impaired fasting glucose and
impaired glucose tolerance may have different pathophysiological mechanisms. Impaired fasting
glucose is thought to be a symptom of insulin resistance in the liver coupled with an insulin
deficit while insulin sensitivity in the muscles remains normal. Impaired glucose tolerance,
however, can be characterized by insulin secretion deficits in the pancreatic beta cells and a
greater insulin resistance in muscles. Essentially, the ability to further break down the
pathophysiology of the disease will allow for a refined approach to identification and treatment
of type 2 diabetes. Rosenstock believes, for example, that “utilizing b-cell function/insulin
secretion and/or insulin resistance to screen and monitor patients would permit more accurate
differentiation and better understanding of the effects of preventive treatments on the underlying
disease process than does measurement of glycaemia.” This approach poses obstacles of its own,
including comparative difficulty of testing, cost and lack of wide-spread availability.

Risk Factors of Type 2 Diabetes
According to Lyssenko and Laakso (2013), type 2 diabetes is a complex medical disorder
resulting from interactions between genetics and environment, and risk factors to include age,
sex, obesity, central obesity, low physical activity, smoking, low fiber diet, high saturated fat
diet, ethnicity, family history, history of gestational diabetes, elevated blood pressure,
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dyslipidemia, and certain drug treatments such as non-selective beta blockers. Although many
independent risk factors are linked to type 2 diabetes, Lyssenko and Laakso also state that there
is ample evidence to suggest a strong genetic component to the disease, pointing to a
monozygotic twin concordance of 70% compared to a dizygotic twin concordance of 20-30%.
Additionally, the lifetime risk of developing diabetes is approximately 40% in the offspring of
one parent with type 2 diabetes and nearly 70% in the offspring two affected parents (Lyssenko
& Laakso, 2013).
Specific to the Native American population, contributing factors can include genetic,
environmental, and behavioral issues. Genetic predisposition to insulin resistance, fetal exposure
to hyperglycemia during pregnancy, sedentary lifestyles, obesity as well as social and physical
stresses caused by living environments are risk factors specifically identified in an article by
McLaughlin (2010). Finally, Alfawaz et al. (2018) identify the manifold correlation between
metabolic syndrome and the development of type 2 diabetes. Metabolic syndrome is a group of
cardiovascular risk factors including central obesity, hyperglycemia, low HDL cholesterol,
hypertriglyceridemia, and elevated blood pressure. Given the high incidence of metabolic
syndrome in the Native American population, further study of metabolic syndrome in the setting
of diabetes is warranted.
Recent advances in genetic testing have broadened the possibilities for identifying
genetic variations that may lead to the development of diabetes, among many other disease
processes. For example, since 2007, genome-wide association studies (GWAS) have identified
more than 65 genetic variants that increase the risk of type 2 diabetes by 10-30% (McCarthy,
2010). The advances in understanding genetic variants associated with type 2 diabetes will be
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advantageous toward the effort of understanding the racial disparity of type 2 diabetes in the
Native American population.
Assessing risk in the Native American population will become increasingly important as
knowledge of the disease process progresses. Today IFG, IGT, and hemoglobin A1c are used as
the primary screening tools for clinicians to determine diabetes status. Equally important is the
clinical assessment, as the clinician utilizes information from the history and physical exam to
identify other factors that contribute to diabetic or prediabetic states. According to Priya (2018),
prediabetes often involves a long asymptomatic period of impaired glucose metabolism. This
period offers an opportunity for patients and providers to identify a prediabetic state based on
screening tests and to begin treatment with lifestyle modifications and pharmacotherapy before
overt diabetes is present and serious complications arise. However, because the patient is
asymptomatic, attention must be focused on the risk factors present at each encounter. Clinicians
must be knowledgeable of the risk factors related to diabetes, as well as the barriers faced by
many in the Native American population in order to successfully exploit the window of
opportunity for treatment in the prediabetic state.

Recommended Therapy Options and Efficacies
According to the American Diabetes Association, diabetes was the 7th leading cause of
death in the United States in 2015 when over 250,000 death certificates listed diabetes as primary
cause of death or a contributing factor. As of 2017, the ADA estimates the total cost of diabetes
in the United States to be approximately $327 billion. With diabetes incidence and prevalence
rising significantly, and the impacts of the disease readily apparent through both clinical and
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economic lenses, the identification of varied therapy options will become exceedingly important
as we look to the future of healthcare for these patients.
Numerous studies have looked at the effects of diet and exercise in diabetic and prediabetic patients, and many have identified benefits of strategic diet and exercise plans to delay
diabetes onset or to improve diabetes symptoms. Today, we recognize the benefits of diet and
exercise to the extent that programs such as the National Diabetes Prevention Program are
tailored around these interventions. Additionally, the ADA’s Standards of Medical Care in
Diabetes (2018) highlights the importance of adequate nutrition, weight management and
physical activity in delaying the onset of diabetes, as well as in treating those already diagnosed
with the disease.
However, the same document also recognizes the need to tailor treatments to social
context—something especially important in the Native American population, given their
typically rural locations, lower socio-economic status, and other social factors that contribute to
the burden of diabetes and other diseases within this population. These factors are important to
consider and will be discussed in greater detail throughout this review.
The recommendation of lifestyle modifications including at least 150 minutes of
moderate exercise weekly (ADA level of evidence “B”) and a decrease of body weight by at
least 5% (ADA level of evidence “A”) have been proven in several studies. These should be the
primary goals for all prediabetic and diabetic patients. Lifestyle modifications were shown to
have clearly defined benefits for participants and can be thought of as the standard by which
other treatment options for diabetes prevention and treatment should be measured. While
metformin has been shown to be beneficial in delaying diabetes in patients with impaired fasting
glucose or impaired glucose tolerance and should be considered the first-line
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pharmacotherapeutic option, it remains less effective than lifestyle modifications. However,
lifestyle modifications are not universally sustainable, according to Srinivasin and Florez (2015).
When lifestyle modifications are not possible due to limiting factors such as disability, finances,
or lack of resources, pharmacotherapy should be considered in all prediabetic and diabetic
patients. According to the ADA, metformin should be considered in all patients with IFG/IGT
who have one or more additional risk factors. Metformin, specifically, should be considered in
all “pre-diabetic” patients who are unable to attain proper lifestyle modifications (ADA, 2018).
While large-scale generalized studies such as the Diabetes Prevention Program are wellintended and informative, the ability to translate these results to specific populations has not yet
been verified. One European study, known as the DE-PLAN study, with publicized results
provided by the Health Program of the European Union (2010), sought to determine if groupbased, non-intensive dietary counselling would be effective in “real-world” community settings.
Through bi-monthly, in-person sessions held in local communities or in places of employment,
this study appeared to show that favorable results, specifically related to reduced body mass,
reduced triglycerides, and improved 2-hour glucose tolerance were possible in a localized
setting.
One DE-PLAN sub-study (Gilis-Januszewska et al., 2018), conducted in Krakow,
Poland, showed that interventions are not easily replicated in local settings where limited
financial and physical resources are apparent. As many in the Native American population reside
in settings where financial and physical resources are often scarce, such interventions may not be
successful as found in the DE-PLAN sub-study noted above. Given these limitations,
recommendations for implementation in a local setting could not be made without further data to
support the approach.
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Diabetes Prevention Program (DPP) studies have been completed and thoroughly studied
in American, Finnish, and Chinese populations. Ramachandran, Snehalatha, Mary, Mukesh,
Bhaskar, & Vijay (2006), applied DPP interventions in the Native Asian Indian population to
determine its efficacy in patients who were younger, leaner, and more insulin resistant than the
previously studied subsets. Using a control group and three intervention groups including a
lifestyle modifications group, a metformin group, and a combined lifestyle modification plus
metformin group, the study followed over 500 participants for an average of 3 years and found
that the results from their study were very similar to those found in previously studied
populations. Both lifestyle modifications and metformin groups benefited from their respective
therapies with relative risk reductions of 28.5% in the lifestyle modifications group, 26.4% in the
metformin alone group, and 28.2% in the lifestyle modification plus metformin group. The
results of the study seemed to prove that similar results from these standard interventions can be
found in a variety of ethnic backgrounds.
The Finnish Diabetes Prevention Study, according to Rosenstock, showed that even at 3
years after the conclusion of the study, participants maintained a 43% risk reduction for
developing diabetes when compared to a placebo group. The cause of this effect is unknown, but
whether the effect was based on the continuation of lifestyle changes or a benefit of a
physiologic change brought about by the intervention, the result is promising for type 2 diabetics
and those with IFG and IGT. Lifestyle interventions, however, can be exceedingly difficult to
maintain over the course of a lifetime. This is documented in a study by Middleton, Anton, and
Perri (2016) that describes the difficulties of long-term adherence to health behavior changes due
to social and behavioral confines, among other barriers. Given the data available regarding risk
reduction and symptom improvement with lifestyle interventions, combined with the knowledge
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of barriers experienced by many in the Native American population, efforts and resources should
be focused on identifying and eliminating obstacles that inhibit implementation and efficacy of
these interventions.
Because minimal research has focused on the Native American population, nativefocused translational studies such as this will help to guide future work related to the
implementation of a robust diabetes prevention program in the Native American community.

Barriers to Success
Many barriers to the implementation of a successful diabetes prevention program exist in
the Native American population. Factors including geographical, financial, social, physical and
psychological must be considered as the search continues for effective therapies and programs to
combat the diabetes epidemic in the Native American communities.
Geography has been identified as a barrier to appropriate healthcare in Native American
communities – specifically those on reservation lands, as these areas are typically remote and
lack adequate healthcare access through Indian Health Services (IHS) systems (Kruse, Bouffard,
Dougherty and Parro, 2016). Additionally, access to specialty care such as cardiovascular and
nephrology services, which are often necessary in the setting of diabetes, are typically available
in tertiary care facilities which are in larger cities even further removed from reservation land.
Related to geography are additional costs of travel, work time lost and peripheral costs such as
childcare while seeking medical care. Kruse et al. (2016) claim that travel time for Native
Americans seeking specialty care often requires between 2 and 5 hours of travel for a single
appointment. With fuel and associated expenses, the patient may incur costs exceeding $200 for
travel alone. Travel costs compound the already bleak financial picture for many Native
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Americans. According to the Economic Policy Institute, the 2017 American Communities
Survey showed that Native American households produce an average annual income of $41,882
– over 30% lower than the national average of $60,336. Although the high cost of healthcare is
reality for all populations throughout the United States, those whose financial status is near or
below the poverty line are disproportionately affected. According to Zhuo, Zhang, Barker,
Albright, Thompson and Gregg (2014), annual medical spending for a diabetic patient in the
United States between 2005 and 2008 (the latest data available) was $13,966. This number was
observed in the general population and does not account for the known additional costs posed by
geography and faced by many Native Americans living on reservation lands.
Another barrier in this population remains access to health insurance. Zuckerman, Haley,
Roubideaux & Lillie-Blanton (2004) describe Indian Health Service (IHS) coverage gaps within
the Native American population, as only approximately 35% of those who identify as AI/AN are
covered by IHS services. While a percentage of Native Americans are covered by employer and
private insurances, the number of uninsured in this population outpaces that of other population
subsets including Caucasians and Hispanics. Zhuo et al., in their general population study, also
identified that diabetics were more likely to be Native American or African American and less
educated, but also more likely to be covered by health insurance than people without diabetes.
Health insurance coverage tends to improve health outcomes for both chronic and acute
conditions. Because this study identified diabetics as being more likely to be covered by health
insurance than non-diabetics, it is possible that this is because individuals without health
insurance are less likely to seek medical care and therefore less likely to be diagnosed.
Additional studies would be needed to consider the unique, and somewhat bizarre result
regarding insurance coverage in this study.
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Education is a social factor impacting Native Americans in the fight to overcome
diabetes. According to the National Indian Education Study (2015), only 49 percent of Native
Americans graduate from high school, compared with 86 percent of the general population.
Although holding a high school diploma or college degree is not a surrogate for diabetes, the
ability to understand the complexity of the disease and the multiple related co-morbidities is
more likely in individuals who have displayed the ability to accomplish these milestones of
education through dedication and determination.
Importantly, the age of newly diagnosed diabetics in the Native American population is
increasingly younger. While this trend is concerning given the lifetime of effects, it also provides
additional insight into the overall disease process. Type 2 diabetes cannot simply be discounted
as a disease of aging but must be considered in patients of all ages. Because of the younger age at
diagnosis, patients will often require the assistance of caregivers in their treatment plan.
Chambers et al. (2018) identified a direct correlation between successful diabetic treatment and
the presence of caregivers who were invested in the care of their youth. In the Native American
population, youth and caregivers often share risk-factors for diabetes.
Other social factors that yield barriers to adequate diabetic care include non-diabetic
family and friends. Because diabetes treatment is complex and time-consuming, and disease
manifestations are often debilitating, the social ramifications of the disease are evident and
socially damaging. Proper diabetic care, according to currently recognized standards, must
include timely monitoring of blood glucose, dietary restrictions and/or modifications and
physical exercise in addition to pharmacological therapy for those that require it. Managing
diabetes properly tends to restrict the lifestyle of diabetic patients and further isolates them from
their non-diabetic friends and family members.
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The demands of the disease are often intrusive to the desired lifestyle of diabetic patients.
As the disease progresses, so do the needs of the patient as damage ultimately leads to dialysis,
vision loss and loss if limbs, among other co-morbidities. Diabetic patients with fulminant
disease often require the assistance of care-takers to attend appointments and even to accomplish
activities of daily living. This inconvenient but necessary reliance on others often leads to
depression, which acts as a psychosocial barrier to proper care. A study by Li, Ford, Strine and
Makdad (2008) reported that despite the benefits of insulin therapy, type 2 diabetics who
required insulin regimens were subject to major depression which is likely related to disease
severity or progression. Because depression often leads to withdrawal from social activities as
the cycle is perpetuated, the disease process worsens and depression increases. This may lead to
decreased compliance with therapies, inadequate treatment and follow-up and, ultimately,
increased morbidity and mortality as the disease process progresses.
Genetic barriers must be further investigated, given the disparate prevalence of diabetes
in the Native American population. Although many of the barriers discussed in this research can
be individually significant, none should have the power to account for the nearly two-fold
increase in diabetes prevalence in Native Americans. Collectively, it might be argued that these
attributes would result in such drastic contrasts when compared to the general population.
However, with the data currently available, assumptions would be required to make such a claim,
given the widespread nature of diabetes in Native American populations, throughout the
generations and across many social and physical confines. If a genetic predisposition to diabetes
in this population were identified, it may help to explain the prevalence of the disease. While
genetic research is ongoing, one study by Roumen, Blaak, & Corpeleijn (2009) concluded that
genetic variation may affect how a person responds to lifestyle interventions based on genotype,
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making the question of lifestyle intervention effectiveness circumstantial – which intervention
recommendations will be the most effective for individuals based on genetic profiles. One such
genotype related to central obesity was identified by Roumen et al. as having a direct correlation
with diabetes diagnosis. Although not specific to the Native American population, the trials
reviewed in this study showed no difference in progression to diabetes once an impaired glucose
tolerance state was identified. Given this information, a genetic involvement predisposing Native
Americans to the diabetes appears increasingly plausible.
Recruitment and retention of participants in personal health management continues to be
a problem in many population subsets across the United States, especially those with low
socioeconomic status. A study by Pratt, Beals, Johnson, Bullock, Manson & Jiang (2018) of
2,901 Native American patients in the Special Diabetes Program for Indians showed an annual
assessment completion rate of only 70%. The study was carried out over 4 years and included 3
enrollment years (cohorts) and a follow up period. With only 70% of the study population
completing the annual program assessments and other limitations such as the voluntary nature
and decreasing participation year over year, the generalizability of the study is limited.
However, given the demographic inclusion of Native Americans only, it is important to consider
the interpretation and how it may play into the overall efficacy of diabetic treatment options.
Another study (Jiang, Johnson, Pratte, Beals, Bullock and Manson, 2018), which also
utilized the Special Diabetes Program for Indians data, identified the difficulties of reaching male
participants for such studies. Although this cohort included over 8,600 participants, over 70%
were female, limiting the usefulness of this study in determining the most effective strategies for
treating diabetes in the Native American population in general. This does, however, highlight an
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additional barrier to proper care – an inability to reach those most-susceptible with the proper
information in order to obtain a buy-in for their own medical care and future health.
Results of these studies demonstrate that the composition of cohorts and their
willingness/ability to participate plays a role in the effectiveness of interventions and implicates
broader lessons for future studies.

Population-Based Studies
One large-scale study - termed the Special Diabetes Program for Indians (SDPI) – included over
2,900 participants representing 80 tribes and 36 health care programs and has provided the
strongest evidence to date regarding translational
effectiveness of general population interventions
within the Native American population. Based
on the Diabetes Prevention Program (DPP)
lifestyle interventions, the SDPI was funded by
the U.S. Congress to assess the effectiveness of
such interventions within a diverse, but wholly
Native American cohort. Diversity of the project
included rural, urban and reservation-swelling participants from 18 states throughout the U.S.
The 16-session Lifestyle Balance Curriculum was offered to all participants and post-curriculum
clinical assessments were completed immediately upon completion of the sessions and annually
thereafter for 3 years. Clinical measures including diabetes incidence, weight loss and changes
in blood pressure were monitored and recorded. The results of the study at three years postcompletion showed significant improvements in blood pressure, lipid levels and weight.
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According to Jiang et al. (2013), these results were observed immediately following session
completion and continued annually thereafter, providing evidence that benefits of such
interventions remain long after cessation of intentional efforts such as the 16-session curriculum.
Evidence of the long-term benefits of these interventions are reflected in the secondary outcomes
of the SDPI study. For example, weight loss was greater than 7% in over one-fifth of the study
population at the end of the 16-session program and 17.5% reached that goal by the end of the
third year. Additionally, there was a direct correlation with weight loss and diabetes incidence
with course completion – diabetes incidence at 3 years post-completion was nearly 25% for
participants who had completed less than 16 sessions, while participants who had completed all
16 sessions displayed an 11% incidence (Jiang, 2013). A follow-up study by Jiang, et al. (2018)
showed a reduction in diabetes incidence of 64% for those that completed the program.
Results of the SDPI program have demonstrated the effectiveness of utilizing
standardized, but intensive therapies to combat the diabetes epidemic in the Native American
population. However, barriers continue to exist for widespread and large-scale prevention
programs – primarily related to the financial and human-resource needs required for
implementation.

Results
Studies of the diagnosis and treatment of prediabetes and diabetes specific to the Native
American population are lacking in both quantity and quality in order to make definitive,
population-specific recommendations for care. Given this, general and other focused-population
studies must be translated and applied to Native American populations in order to understand
with greater clarity the potential benefits of therapies in this setting. However, because no
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evidence was found through this study to refute the benefits of the American Diabetes
Association’s 2018 recommendations in Native Americans, healthcare providers should
encourage all patients to abide by these guidelines including regular exercise, healthy eating and
self-management education.
Importantly, Native Americans face many barriers to proper diabetes care including
geographical, financial, and social factors which must be recognized by not only the patient and
provider, but also by policymakers, tribal leaders and the healthcare and health insurance
industries as efforts are made to reduce the burden of diabetes on individuals and society.
Because diabetes is a life-long disease, patients who are diagnosed and treated earlier, and those
who can maintain prolonged lifestyle interventions will ultimately experience fewer
complications and hospitalizations and will incur lower healthcare costs compared to those who
are diagnosed later and who are unable to sustain lifestyle interventions.
Finally, it is paramount that all diabetic patients are treated as individuals, and not as a
generalized population. Inherently, however, research studies provide a greater understanding of
populations, not individuals. While generalized information is certainly advantageous in
observing patterns and identifying possibilities, it must then be applied to the individual in a way
that meets patient-specific needs. It is this specificity that will ultimately lead to successful
treatment of diabetes and improve the lives of countless individuals diagnosed with, or yet-to-be
diagnosed with diabetes.

Clinical Application
Apparent throughout this study was evidence that the Native American population, in
general, faces numerous barriers that limit the opportunity for early diagnosis and proper
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treatment of diabetes. These barriers lead to an increased prevalence of this disease process
within the Native American community and ultimately to higher morbidity and mortality.
Further, studies point to identification of risk factors, specifically obesity, in Native American
youth. Because of the long-term health impact of diabetes, observation of these risk factors at a
younger age must be acknowledged as a significant finding by clinicians in the primary care
setting.
Although this review did not produce a defined treatment plan for diabetes specific to the
Native American population, several highlights appear to be equally as effective within this
population as in the initial respective study population. Specifically, the ADA’s Standards of
Medical Care in Diabetes 2018 guidelines identify that physical exercise, diet modifications, and
diabetes self-education should be implemented in all patients with diabetes and pre-diabetes.
Patients with additional risk factors, and those who may be physically unable to undertake
adequate exercise may also benefit from the addition of metformin to their treatment plan.
Large-scale programs for the identification of diabetes and risk factors in the Native
American population have been only moderately successful, owing their shortcomings to a high
attrition rate and lack of generalizability. Until further research can identify best-practice
methods by which to successfully identify and treat Native Americans with diabetes, clinicians
must take a one-on-one approach to ensure that patients are receiving the best possible care.
Suggestions identified in this study include risk-factor screening at every office visit and annual
follow-up for those with significant risk factors but not yet diagnosed with diabetes or prediabetes. Finally, opportunities for patient education must be capitalized within the office setting.
Compliance with any treatment plan remains a personal decision. However, educating patients
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on the risk factors, disease process, complications and treatment options remains vital as
informed patients can make informed decisions.
Conclusion
Diabetes prevalence in Native Americans is disproportionate to the general population.
Native Americans are being diagnosed with diabetes at a younger age and with more comorbidities than in decades past. This data justifies the focused attention and resources necessary
to identify and treat risk factors in this population and throughout the world. Given the
ramifications of this disease on lifestyle and overall health, as well as the associated economic
and financial burdens, more research is needed to identify specific pathophysiology, risk factors
and barriers to proper and effective treatment in this population.
While foundational studies specific to the Native American population are limited,
baseline data is available that has identified known barriers to ideal diabetes care and proper
healthcare in general. Additionally, general population studies have demonstrated effective
treatment options for delaying the onset of diabetes and for treating the disease after diagnosis
and translational studies have failed to prove that the current best-practices would be ineffective
in the Native American population.
There remains much progress to be made in the effort to fight the diabetes epidemic in
the Native American population. Based on currently available research, Native American
diabetic patients should be treated using general guidelines such as the ADA’s Standards of
Medical Care in Diabetes, as research has shown a benefit to lifestyle modifications in all
patients, regardless of ethnicity. Additionally, pharmacotherapy with metformin should be
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recommended in all patients with IFG/IGT who have additional risk factors, as well as in those
who are physically unable to complete appropriate lifestyle modifications.
Barriers addressed in this paper can be directly attributed to patients, providers,
caregivers, communities and institutions. To ensure that individual barriers are identified and
overcome, and effective therapies are provided, successful treatment of diabetes and prediabetes
necessitates active involvement and collaboration of these entities. Future research should be
directed at discovering solutions through collaboration and shared resources.
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